QLINE2026-11-12QLINE2026-11-122026-11-12QLINE2026-11-12in-capmkt:FinancialYear1MemberQLINE2026-11-12in-capmkt:FinancialYear2MemberQLINE2026-11-12in-capmkt:FinancialYear3MemberQLINE2026-11-122026-11-12in-capmkt:FinancialYear1MemberQLINE2026-11-122026-11-12in-capmkt:FinancialYear2MemberQLINE2026-11-122026-11-12in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure000000Q-LINE BIOTECH LIMITEDQLINENOTLISTEDINE1G2W01011NewAcquisition (including agreement to acquire)true2026-11-1219:00:002026-11-12Q Line Biotech LimitedListed Entity (self)Heidelco Medicore Private Limited57000000030000000380000000true2026-11-122026-11-12falsetrueCertain Directors and members of Q Line Biotech Limited are also members of Heidelco Medicore Private Limited.trueManufacturingThe acquisition forms part of the Company's strategic investment consolidation and expansion plan, aimed at strengthening group synergies and enhancing operational, financial and administrative efficiencies. It is intended to improve marketing and manufacturing capabilities, promote better corporate governance and drive operational excellence and profitability. The acquisition of 70% equity shares will make HMPL a subsidiary of the Company.NotrueMaximum three months from the date of signing the SPAs and other transaction documents/agreements, extendable by mutual agreement.Cash260000000Aggregate consideration of ₹26,63,51,750 payable in cash in one or more tranches on closing. Valuation is based on Net Asset Value (NAV) as on 30.09.2026.26000000000.70.7HMPL is a private limited company incorporated on 26 April 2013, engaged in manufacturing and supply of Critical Care Instruments and consumables. The company operates in India.2013-04-262025-202610800000002024-20255800000002023-2024500000000INDIA